tiprankstipranks
Advertisement
Advertisement
Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
PremiumThe FlyLeerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
1M ago
Regulatory Tailwinds and Clinical Momentum Support Buy Rating on Fulcrum Ahead of Key 2Q26 FDA Milestones
Premium
Ratings
Regulatory Tailwinds and Clinical Momentum Support Buy Rating on Fulcrum Ahead of Key 2Q26 FDA Milestones
1M ago
Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study
Premium
Company Announcements
Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study
2M ago
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel
PremiumThe FlyFulcrum Therapeutics move lower ‘overdone,’ says Stifel
2M ago
Truist remain buyers of Fulcrum Therapeutics shares on weakness
Premium
The Fly
Truist remain buyers of Fulcrum Therapeutics shares on weakness
2M ago
Fulcrum Therapeutics announces results from Phase 1b PIONEER trial of pociredir
Premium
The Fly
Fulcrum Therapeutics announces results from Phase 1b PIONEER trial of pociredir
2M ago
JPMorgan large/SMid cap biotech analysts hold analyst/industry conference call
PremiumThe FlyJPMorgan large/SMid cap biotech analysts hold analyst/industry conference call
3M ago
De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data
Premium
Ratings
De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data
3M ago
Fulcrum Therapeutics updates strategy on lead sickle cell therapy
Premium
Company Announcements
Fulcrum Therapeutics updates strategy on lead sickle cell therapy
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100